Cue Biopharma Inc (CUE)
1.705
+0.22
(+14.81%)
USD |
NASDAQ |
Nov 05, 16:00
1.74
+0.04
(+2.05%)
After-Hours: 18:14
Cue Biopharma Profit Margin (Quarterly): -382.7% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -382.7% |
| March 31, 2024 | -719.1% |
| December 31, 2023 | -737.7% |
| September 30, 2023 | -524.0% |
| June 30, 2023 | -954.1% |
| March 31, 2023 | -7.01K% |
| December 31, 2022 | -9.66K% |
| September 30, 2022 | -16.11K% |
| June 30, 2022 | -50.80K% |
| March 31, 2022 | -1.43K% |
| December 31, 2021 | -101.6% |
| September 30, 2021 | -542.5% |
| June 30, 2021 | -375.3% |
| Date | Value |
|---|---|
| March 31, 2021 | -805.2% |
| December 31, 2020 | -2.34K% |
| September 30, 2020 | -1.42K% |
| June 30, 2020 | -1.01K% |
| March 31, 2020 | -1.42K% |
| December 31, 2019 | -849.8% |
| September 30, 2019 | -710.4% |
| June 30, 2019 | -902.6% |
| March 31, 2019 | -3.05K% |
| December 31, 2018 | -3.52K% |
| September 30, 2018 | -2.80K% |
| June 30, 2018 | -4.24K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-50.80K%
Minimum
Jun 2022
-101.6%
Maximum
Dec 2021
-5.12K%
Average
-954.1%
Median
Jun 2023
Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 14.22% |
| Arbutus Biopharma Corp | -1.15K% |
| GlycoMimetics Inc | -- |
| FibroGen Inc | -30.69% |
| Cidara Therapeutics Inc | -30.20K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -132.3% |
| Return on Assets | -78.30% |
| Return on Invested Capital | -107.6% |
| Operating Margin (Quarterly) | -390.6% |
| Return on Net Operating Assets | -536.4% |